Drug Trial Radar · NCT06589635
A Drug-Drug Interaction (DDI) Study of ADC189 With Itraconazole in Healthy, Adult Subjects
Last checked: Nov 19, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jul 16, 2024
Primary completion
Sep 11, 2024
Study completion Sep 11, 2024
Sponsor
- Lead sponsor
- Jiaxing AnDiCon Biotech Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to answer how repeat doses of itraconazole impact the pharmacokinetics, safety, and tolerability of single doses of ADC189 in healthy adults. Participants in this study will complete screening assessments within 14 days before the first dose of ADC189. Participants will be admitted to the clinical pharmacology center (CPC) and complete 2 periods of treatments. On Day 1 and 26, each participant will receive a single oral dose of ADC189 (45mg), under fasting condition On Day 22, all participants will receive oral doses of itraconazole 200 mg (bid), after meal. From Day 23 to Day 25, and Day 26-D39, participants will receive itraconazole 200 mg(qd). Blood and safety assessments will continue for 336-hours after dosing on Day 1 and Day 26. Participants will receive a telephone follow-up on D47 (±3) days for a final visit.
Conditions
- Healthy Adults
Interventions
ADC-189 and ItraconazoleDrug
Part 1: Day 1, fasting condition, 45 mg ADC189, administered orally Part 2: Day 22, 200 mg itraconazole bid, taken orally after meals. Day 23-Day 25, 200 mg itraconazole was taken orally after meals. Day 26, 45 mg ADC-189 and 200 mg itraconazole was taken orally after meals. Day 27-Day 39, 200 mg itraconazole was taken orally after meals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC[0-∞] of ADC-189Time frame: Part 1: Day 1 to Day 15; Part 2: Day 21 to Day 40
- Cmax of ADC-189Time frame: Part 1: Day 1 to Day 15; Part 2: Day 21 to Day 40
- AUC[0-t] of ADC-189Time frame: Part 1: Day 1 to Day 15; Part 2: Day 21 to Day 40
- Adverse events (AEs)Time frame: Day 1 to Day 43
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affilicated Hospital of Bengbu Medical University
Bengbu, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.